Hong Jin, Mao Yan, Chen Xiaosong, Zhu Li, He Jianrong, Chen Weiguo, Li Yafen, Lin Lin, Fei Xiaochun, Shen Kunwei
Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Second Road, Shanghai, 200025, China.
Center of Diagnosis and Treatment for Breast Disease, Affiliated hospital of Qingdao University, 59 Haier Road, Qingdao, 266061, China.
Tumour Biol. 2016 Mar;37(3):4135-42. doi: 10.1007/s13277-015-4233-1. Epub 2015 Oct 21.
Inflammation and tumor immune microenviroment are critical factors for prognosis in numerous cancers. The aim of this study was to determine the prognostic value of preoperative neutrophil-to-lymphocyte ratio (NLR) in breast cancer. We performed a retrospective analysis of 487 patients diagnosed with primary breast cancer at Shanghai Ruijin hospital from January 2009 to December 2010. Hematological parameters before surgery, clinicopathological data, and survival status were obtained. Survival analysis was used to evaluate the prognostic value of NLR. The optimal cutoff value was determined as 1.93 for NLR and the median follow-up time was 55.0 months. On univariate analysis, patients with high NLR (>1.93) had worse 5-year disease-free survival (DFS) compared to those with low NLR (77.9 vs 88.0 %, p = 0.002). Regarding overall survival, there was no significant difference between patients with high NLR and low NLR, with 5-year overall survival of 90.8 and 91.7 % (p = 0.707). In triple-negative breast cancer, patients with high NLR was associated with worse 5-year DFS compared with patients with low NLR (63.4 vs 84.9 %, p = 0.040). Mutivariate analysis revealed that NLR was an independent prognostic factor for DFS in breast cancer (HR = 1.867, 95 % confidence interval; (95%CI) = 1.155-3.017, p = 0.011). Preoperative NLR is an independent predictor of DFS in breast cancer patients, especially in triple-negative subtype. Further studies are required to validate the prognostic value of NLR before clinical application.
炎症和肿瘤免疫微环境是众多癌症预后的关键因素。本研究旨在确定术前中性粒细胞与淋巴细胞比值(NLR)在乳腺癌中的预后价值。我们对2009年1月至2010年12月在上海瑞金医院诊断为原发性乳腺癌的487例患者进行了回顾性分析。获取术前血液学参数、临床病理数据和生存状态。采用生存分析评估NLR的预后价值。确定NLR的最佳截断值为1.93,中位随访时间为55.0个月。单因素分析显示,高NLR(>1.93)的患者5年无病生存率(DFS)低于低NLR患者(77.9%对88.0%,p = 0.002)。关于总生存率,高NLR和低NLR患者之间无显著差异,5年总生存率分别为90.8%和91.7%(p = 0.707)。在三阴性乳腺癌中,高NLR患者的5年DFS较低于NLR患者更差(63.4%对84.9%,p = 0.040)。多因素分析显示,NLR是乳腺癌DFS的独立预后因素(HR = 1.867,95%置信区间;(95%CI)= 1.155 - 3.017,p = 0.011)。术前NLR是乳腺癌患者DFS的独立预测指标,尤其是在三阴性亚型中。在临床应用前,需要进一步研究验证NLR的预后价值。